Panbela Therapeutics (NASDAQ:PBLA) Stock Price Up 2.4% – Still a Buy?

Panbela Therapeutics, Inc. (NASDAQ:PBLA)’s share price rose 2.4% during mid-day trading on Tuesday . The company traded as high as $0.34 and last traded at $0.34. Approximately 5,495 shares traded hands during trading, a decline of 98% from the average daily volume of 238,504 shares. The stock had previously closed at $0.34.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “neutral” rating on shares of Panbela Therapeutics in a research note on Thursday, August 15th.

Panbela Therapeutics Stock Performance

The business has a 50-day simple moving average of $0.35 and a 200-day simple moving average of $0.39.

Panbela Therapeutics (NASDAQ:PBLA) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($1.47) earnings per share for the quarter, beating the consensus estimate of ($2.07) by $0.60.

About Panbela Therapeutics

Panbela Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company’s lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial.